Kidney function may change how D-2570 works in the body

NCT ID NCT07715175

Not yet recruiting Knowledge-focused Sponsor: InventisBio Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jul 20, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This study looks at how the drug D-2570 moves through the body in people with reduced kidney function compared to those with normal kidneys. About 40 adults aged 18 to 70 will receive a single dose of D-2570. Researchers will measure drug levels in the blood and monitor for side effects to understand how kidney impairment affects the drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a single dose of D-2570
What this could lead to: If successful, this study could help determine safe dosing of D-2570 for patients with kidney impairment.
What could go wrong: This is an early-phase, small study focused on drug levels and safety, not on treating any disease. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

impaired renal function disease kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RENAL IMPAIRMENT

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

The First Affiliated Hospital of Anhui Medical University

Hefei, Anhui, 230022, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.